Catalog No.: PC-38189Not For Human Use, Lab Use Only.
DS-1001b (DS1001b) is a potent, selective, BBB-permeable and orally bioavailable mutant IDH1 inhibitor with IC50 of 8.4/11 nM against IDH1 R132H/R132C mutants.
DS-1001b (DS1001b, Safusidenib) is a potent, selective, BBB-permeable and orally bioavailable mutant IDH1 inhibitor with IC50 of 8.4/11 nM against IDH1 R132H/R132C mutants.
DS-1001b strongly inhibited mutant IDH1, but not wild-type IDH1 or mutant IDH2 (IC50>10 uM).
DS-1001b impairs the proliferation of IDH1 mutant GBM cells and induces differentiation in a subcutaneous PDX model, but not the growth of IDH wild-type GBM.
DS-1001b permeates the BBB and inhibits tumor growth in an orthotopic PDX model.
